Share this video  

GU Cancers 2021 | Highlights in urothelial cancer for ASCO GU 2021

Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, shares her highlights in urothelial cancer from the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2021. Dr Gupta discusses the endpoints, results, and importance of the Phase III CheckMate 274 trial (NCT02632409). The key finding of this trial was that nivolumab improved disease-free survival in the overall population as well as the PD-L1 high population of patients, but further studies are needed to determine overall survival rates with nivolumab. This interview took place during the 2021 Genitourinary Cancers Symposium.